SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    N. M. Intagliata, Z. H. Henry, H. Maitland, N. L. Shah, C. K. Argo, P. G. Northup, S. H. Caldwell, Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation, Digestive Diseases and Sciences, 2016,

    CrossRef

  2. 2
    Sunil Dacha, Ram M. Subramanian, Critical Care Management in Cirrhosis, Current Hepatology Reports, 2015, 14, 1, 60

    CrossRef

  3. 3
    C. Lau, C. Burd, D. Abeles, D. Sherman, Decision making in venous thromboembolism prophylaxis: Is LWMH being inappropriately withheld from patients admitted with chronic liver disease?, Clinical Medicine, 2015, 15, 1, 31

    CrossRef

  4. 4
    Armando Tripodi, Hemostasis abnormalities in cirrhosis, Current Opinion in Hematology, 2015, 22, 5, 406

    CrossRef

  5. 5
    Federica Cerini, Javier Martínez Gonzalez, Ferran Torres, Ángela Puente, Meritxell Casas, Carmen Vinaixa, Marina Berenguer, Alba Ardevol, Salvador Augustin, Elba Llop, Maria Senosiaín, Càndid Villanueva, Joaquin de la Peña, Rafael Bañares, Joan Genescá, Júlia Sopeña, Agustín Albillos, Jaume Bosch, Virginia Hernández-Gea, Juan Carlos Garcia-Pagán, Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study, Hepatology, 2015, 62, 2
  6. 6
    Greg C.G. Hugenholtz, Patrick G. Northup, Robert J. Porte, Ton Lisman, Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?, Blood Reviews, 2015, 29, 2, 127

    CrossRef

  7. 7
    Wilma Potze, Ton Lisman, Issues With Monitoring of Unfractionated Heparin in Cirrhosis, Therapeutic Drug Monitoring, 2015, 37, 2, 279

    CrossRef

  8. 8
    Wilma Potze, Robert J Porte, Ton Lisman, Management of coagulation abnormalities in liver disease, Expert Review of Gastroenterology & Hepatology, 2015, 9, 1, 103

    CrossRef

  9. 9
    J. Shatzel, P. S. Dulai, D. Harbin, H. Cheung, T. N. Reid, J. Kim, S. L. James, H. Khine, S. Batman, J. Whyman, R. C. Dickson, D. L. Ornstein, Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study, Journal of Thrombosis and Haemostasis, 2015, 13, 7
  10. You have free access to this content10
    Dominique-C. Valla, Pierre-E. Rautou, The coagulation system in patients with end-stage liver disease, Liver International, 2015, 35,
  11. 11
    Ton Lisman, Low molecular weight heparin in management and prevention of portal vein thrombosis, Thrombosis Research, 2014, 134, 4, 761

    CrossRef

  12. 12
    Raffaele Licinio, Mariabeatrice Principi, Giuseppe Losurdo, Nicola Maurizio Castellaneta, Enzo Ierardi, Alfredo Di Leo, Low Molecular Weight Heparin in Portal Vein Thrombosis of Cirrhotic Patients: Only Therapeutic Purposes?, The Scientific World Journal, 2014, 2014, 1

    CrossRef

  13. You have free access to this content13
    Nicolas M. Intagliata, Stephen H. Caldwell, Management of disordered hemostasis and coagulation in patients with cirrhosis, Clinical Liver Disease, 2014, 3, 6
  14. 14
    Filipe Nery, Dominique Valla, Splanchnic and Extrasplanchnic Thrombosis in Cirrhosis: Prophylaxis vs Treatment, Current Hepatology Reports, 2014, 13, 3, 224

    CrossRef

  15. 15
    Federica Cerini, Juan Carlos Garcia-Pagán, Thromboprophylaxis with heparin in hospitalized patients with cirrhosis: friend or foe, Liver International, 2014, 34, 7